Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

BACKGROUND: Treatment of heart failure with reduced ejection fraction (HFrEF) has been revolutionized by angiotensin receptor/neprilysin inhibitor (ARNI). ARNI has been shown to significantly reduce morbidity and mortality in a large, randomized controlled trial. However, real-world evaluation of AR...

Descripción completa

Detalles Bibliográficos
Autores principales: Rattanavipanon, Wipharak, Sotananusak, Thanyaluck, Yamaae, Fairus, Chandrsawang, Arisa, Kaewkan, Pitchapa, Nathisuwan, Surakit, Yingchoncharoen, Teerapat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254265/
https://www.ncbi.nlm.nih.gov/pubmed/34215190
http://dx.doi.org/10.1186/s12872-021-02145-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254265/
https://www.ncbi.nlm.nih.gov/pubmed/34215190
http://dx.doi.org/10.1186/s12872-021-02145-9

Ejemplares similares